Gilead says additional data on remdesivir shows improved clinical recovery

This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEC0409P_M.jpg

The company said the finding requires confirmation in prospective clinical trials.

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.

Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.

Gilead shares were up nearly 2% at $76.14 in trading before the bell.

Add Comment